Global Estrogen Replacement Therapy Market Size, Forecast, and Trend Highlights Over 2025-2037
Estrogen Replacement Therapy Market size was valued at USD 12.8 billion in 2024 and is projected to reach USD 26.1 billion by the end of 2037, rising at a CAGR of 6.6% during the forecast period, i.e., 2025-2037. In 2025, the industry size of estrogen replacement therapy is evaluated at USD 13.7 billion.
The enlarging female population, entering menopause, around the world is one of the the primary drivers behind the growth of the market. In this regard, the WHO predicted more than 1.3 billion women to be at peri- or post-menopausal stage by 2030. This demography is also fueled by the rapid aging in every region, where a significant proportion of the net volume of citizens falls under the age group of 65 and over. On the other hand, the growing incidences of osteoporosis and its negative impact on the quality of life, particularly among older people, are also contributing to the sustaining demand. For instance, in 2025, Germany alone recorded approximately 4.2 million such cases, that underwent estrogen replacement therapy (ERT), since 2018, according to the Robert Koch Institute (RKI).
Several factors, including API supply disruption and compliance delay, create inflation in payers' pricing in the market. This upward trajectory in financial exhaustion can further be displayed by a 4.3% year-over-year (YoY) increment in the producer price index (PPI) for hormone therapies between 2023 and 2024. Subsequently, this upstream flow was notably followed through the consumer price index (CPI) for ERT products with a 5.9% rise. Thus, the cost volatilities during manufacturing have the potential to obstruct wide adoption in this sector by creating an economic barrier for both producers and consumers. However, both health organizations and companies are increasingly engaging their resources in extensive R&D and cost-optimized production to mitigate this disparity.
